Get started

Jdcom

JD is still strong for longI’ve been watching this company for a long time, and even have long position at the price of 65.6. JD.com made clear impulse up by Feb 2021 after which it began to decline. At the moment, the entire decline after ATH I can count as zigzag ABC, where B is triangle. From level 61.65 (+ reaction from 50% Fibo level) the price formed leading diagonal plus ABC correction. After that, the price bounced again and met resistance in the middle of the channel formed by the previous waves. BTW, what is interesting - JD didn’t show us a fairly strong decline while NASDAQ index corrected well down. So, for now I have 2 scenarios: 1. At the main scenario, I think that the price has formed wave 1 of (3) and expect further upward movement from the channel and extension of the waves. 2. But I also consider an alt. scenario in which wave (2) isn’t completed yet and price want to form wave X (as ZZ) of a double zigzag WXY. In fact, it confuses me that wave (2) ended so quickly and perhaps the price will meet good resistance at the border of the channel. I’ll watch the volumes and further price action near resistance zone (92.6 - 94.5).
NASDAQ:JDLong
by Ewangilist
1
$JD Inverse Head and ShouldersNew trader here, would greatly appreciate any feedback on my rudimentary analysis. I have been watching $JD and am proposing the potential development of an Inverse Head and Shoulders pattern. I would now be looking for a pullback from the neckline (top purple box ~$71) to the shoulder line (middle purple box ~$65), before a break of the neckline to enter a long position. I still haven't really nailed the best way of setting targets but suppose you could use a risk reward SL-TP . Additionally, based on another community post, I have been exposed to a bullish signal within the RSI indicator forming inline with the pattern. Thanks in advance. *Not financial advice*
NASDAQ:JDLong
by Angus_Ed
JD, 6 Jan. Two buy levels.JD has lost a third of its value in just over a month. Let’s take a look if we can pick the stock up over the next days. Elliott: We are looking for a wave C with 5 sub-waves. We can count a completed 5-wave move to the downside now. Alternatively we expect one more wave to completion. These two interpretations give us two potential buy levels. Geometry: Price bounced at the lower boundary of the upward channel, which is the .5 fib mark of the downward facing channel. Oscillators: The RSI shows a bullish divergence. The Stochastic is oversold for over a month and due to move up. How to trade it: The two levels (green arrows) give us excellent risk-reward ratios to try long positions with tight stop losses. The lower level at 54 is more likely to hold when we expect an expanded flat correction. JD needs to re-gain the 21 day MA and hold it in order to further increase long exposure safely.
NASDAQ:JDLong
by UnknownUnicorn12250317
4
JD.com's Healthcare Unit Prepare for Next Battle Affected heavily by recent technological advancements, the sector may soon attract Chinese regulators' attention. Background 2021 turned out to become a positive year for China's healthcare industry, where the gigantic demand stems from the aging population, growing individual wealth, and – more importantly – the COVID-19 crisis' aftermath. The market has grown consistently; in 2020, the growth rate slumped to 7.2% due to the massive lockdowns, although it is expected to rise back to 17.6% in 2021 with a total market size of CNY 8.7 trillion. Despite this, the market remains relatively undeveloped – since 2016, the Chinese authorities have been working on creating a CNY 16 trillion healthcare ecosystem by 2030. Online healthcare is in the limelight The pandemic challenged people's sense of well-being and facilitated their desire and determination to become more active and engaged in managing their health, which also boosted the need for remote medical consultations and online medicine sales. According to Deloitte, the portion of consumers who have used virtual visits rose from 15% to 19% from 2019 to early 2020, then jumped to 28% in April 2020. In fact, consumers plan to continue using the – 80% of the Deloitte survey respondents are likely to keep using other online services even post COVID-19. Jessica Tan, co-CEO of Ping An Group, once said that around 20% to 25% of healthcare services in China could be moved to the online space. This will present new opportunities to the most competitive businesses in this field. Among these, JD Health (6618:HK) and Alibaba Health (0241:HK) are two tech giant-backed companies that have ridden this surging wave quite well. The latecomer, JD Health, is moving really fast – only four months' independent operation since May 2019 before it filed a public offering. In August 2020, JD Health ranked 35th on Hurun Global Unicorn Index 2020 with a valuation at CNY 50 billion, which crowned it as the world's youngest unicorn. Different from traditional platforms, JD Health has established various online and offline integrated businesses, including JD Pharmacy, JD Health Internet Hospital and Pharmacy Alliance. How does JD.com compare in healthcare endeavors? Financial performance In September 2021, JD Health released its interim financial report with relatively strong results. Its total revenue increased by over half (55.4%), from CNY 8.8 billion in H1 2020 to CNY 13.6 billion in H1 2021, which was primarily due to the increase in revenue from sales of pharmaceutical and healthcare products within the reporting period. In fact, this continuous upward trend also shows in its gross profit for the past four fiscal years, although the loss enlarged even further in 2020 when compared with the previous years. Another catalyst for the growth could be the increase in JD Health's number of Annual Active User (AAU) accounts. As of June 30, 2021, the AAUs in the past 12 months reached 109 million, representing a net addition of over 18.8 million as compared with that of 2020. The growing number also shows that the stickiness of users has been well improved as well as its brand awareness. In other words, JD Health's constant investment in marketing activities – its selling and marketing expenses almost doubled for two consecutive fiscal years – finally began to work. JD's supply chain infrastructure casts its core barrier Although JD Health is relatively inferior to its competitor in terms of annual active users – 109 million as of June 30, 2021 – JD Health's revenue is all the way higher than that of its closest competitor, Alibaba Health, more specifically, the revenue as nearly two times higher. One booster is its complete business structure. Integrating B2B/B2C/O2O businesses, JD Health can have more wings – for example, along with the retail pharmacy, JD Health also offers its own family doctor services, online hospital services as well as smart healthcare solutions. Through the integration of pharmaceutical retail businesses and online healthcare services, the medical products users also become target customers for other consumption healthcare units, and vice versa; a closed cycle hence is developed and can also be seen in its ever-growing operating income at a CAGR of 11%. JD Logistics is another catalyst supporting the healthcare unit's strong performance, being one of the leading supply chain players in the field of medicine now. Through JD Logistics, JD Health is able to connect with upstream, midstream and downstream enterprises: from industrial enterprises and healthcare institutions to offline pharmacies and dental clinics. This absolute advantage over comparable companies enables JD Health to further cut its fulfillment costs to around 10% of total revenue, which is related to warehousing, logistics and customer service expenditures incurred by the self-operated pharmaceutical business. Future in the mist The future won't be easy for both Alibaba Health and JD Health, as the competition is intensifying. Except for the 'peer pressure,' some inherent problems exist in the essence of most healthcare services – those are mainly related to professionalism, trust and quality. It is partly because of the particularity of healthcare services and pharmaceutical drugs along with the recent market chaos, the government has tightened supervision increasingly, more than ever before. Rory Green, a China economist at TS Lombard, said that the healthcare sector is the only one not hit by regulatory scrutiny yet but is particularly vulnerable, which may possibly make it the next target. For the full article with the charts, please visit the original link.
HKEX:6618
by EqualOcean
JD's 'Hourly Purchase' Plan Boosts Dada Group's Revenue GrowthLooking ahead to the fourth quarter of 2021, Dada Group expects its total revenue, assuming Dada Express's Last-mile delivery services perform consistently, to grow from between 88% to 97% YoY. On October 12, JD.com's 'hourly purchase' business, jointly created by JD.com and Dada Group, was officially launched. The merchant resources of JD Daojia can be connected to the 'nearby' entrance of JD's main website. After users place orders through the JD website, the later order delivery service will be completed by Dada Group. Dada Group was founded in 2014 as a local instant retail and delivery platform. Dada Express is the local instant delivery platform of Dada Group, providing merchants and consumers with omnichannel fulfillment solutions and local instant delivery services integrating warehousing, picking and distribution. At present, Dada Express has covered more than 2,300 counties, districts and cities in China, serving more than 1.4 million merchant users and 70 million individual users. Relying on the distribution of Dada Express and its massive retail partners, JD Express now provides consumers with a one-hour delivery service for products, including supermarket convenience, fresh fruits, vegetables, medicine, cake baking, flowers and other goods.
NASDAQ:JD
by EqualOcean
JD.com Analysis 15.10.2021Hello Traders, welcome to this free and educational analysis. I am going to explain where I think this asset is going to go over the next days/weeks and where I would look for trading opportunities. If you have any questions or suggestions which asset I should analyse tomorrow, please leave a comment below. I would also appreciate, if you would smash that like button and help me to create more free analysis like that. Thank you for watching and I will see you tomorrow!
NASDAQ:JD
by basictradingtv
6
JD.com Published 2021 Q2 Financial ResultsThe overall revenue performance is positive. According to JD's (JD:NASDAQ) financial announcement for the second quarter of 2021: - The net income rose by 26.2%, reaching CNY 253.8 billion. - The net profit attributable to ordinary shareholders was CNY 790 million, compared with CNY 16.4 billion in the same period in 2020. While under non-GAAP, it was CNY 4.6 billion, down from CNY 5.9 billion in the same period last year. - The operating revenue slumped to CNY 300 million from CNY 5 billion in the same period last year. - As of June 30, 2021, the number of employees in JD.com listed companies and non-listed companies was nearly 400,000, becoming the company with the largest number of employees in domestic private enterprises. - For the twelve months ending June 30, 2021, JD’s cash flow was CNY 38.9 billion (up from CNY 26.3 billion previously). - Excluding the impact of JD Baitiao on the operating cash flow, the free cash flow for the twelve months ending on June 30, 2021, was CNY 31.9 billion, compared with CNY 22.7 billion in the same period last year. - For the twelve months ending June 30, 2021, the number of active purchasers of JD.com was 532 million, achieving a net increase of 115 million over the same period last year. It also set a record for attracting 32 million new users in a single quarter. Among them, more than 70% of the products purchased by active users are delivered to third- to sixth-tier cities.
NASDAQ:JD
by EqualOcean
JD.com HEALTH ~ Looking for movement to appear soon... JD HEALTH as retail pharmacy has started to be online, and notice increase of sale retail is now online multiple supported showing JD Health have been ranging near the IPO price, premature Head and Shoulder is forming up. Currently it's at lower zone, expecting as break out happening soon with the lower range support to TP1 $124 and above.. If support break we might be looking under IPO prices. Circle indicate possible low. Good Luck!!
HKEX:6618Long
by JarvisTan
2
JD.com bullish long termAnother stock that's in my portfolio is JD.com (NASDAQ: JD), the national e-commerce giant second only to Alibaba (NYSE: BABA) in gross merchandise volume. It did remarkably well in the first quarter, when China saw its first economic contraction since the government began reporting statistics. It did even better in the second quarter as the wheels of the economy started speeding up again. The covid period has really helped many e-com boost their revenue and profit. Amazon is one of them as well. That said, I feel JD.com has huge potential and definitely a stock worth holding long term. Even once covid is over, I highly believe that users of e-com will still continue using it and they will continue to be profitable. A good entry point if it ever retrace would be around $64 - $70. Although I feel that there's a chance that it will just continue its rally if Covid cases continues to increase and no vaccine is discovered.
NASDAQ:JDLong
by Trader_hao
2016 Resistance Line still alive and doing its workI am really bullish on this stock long term, good management team, good business model and a very strong development in the AI sector. But, given the pandemic we are still assisting all over the world right now, the stock has just been riding the wave - similarly to amazon, shopify, ebay and all other ecommerce platforms. But I think it's now time for a little pullback before it keeps its bull trend. We can see the same very strong resistance line dated from 2016 that has rejected the price for 4 times already since JD's IPO . If you zoom in and have a look at the 1hr or 30min chart, you'll see that the price has struggled to stay above that line the past week. I got in this trend when the price was still at 35 but, while I am 65% up since a couple of months ago, I am still not closing the trade because I am also a long term investor and know the potential of this business. But, considering this recent surge in price movement, I am going short on my trading account, wait for that pull back and then, go long again.
NASDAQ:JDShort
by joaopdias
Previous Target MET for JD ~ Next Alibaba???First off, please don't take anything I say seriously or as financial advice. As always, this is on opinion based basis. That being said, here are my thoughts. Last drawing/chart trendline prediction I did, the pattern followed almost the exact same price correlation as a short when I was bullish. I still am expecting JD to even have some more growth in this whole "golden" period for internet retail. I may even say Alibaba may need to watch their backs on where JD is heading. They already been having insane revenue growth the past few years. Infact if you compare the revenue vs. market cap action going on, JD is either considerably under rated or Alibaba is way too over valued. I don't think Alibaba is at all over valued, which leads me to believe that JD is under rated.
NASDAQ:JDLong
by gamer456148